INTRODUCTION AND OBJECTIVES LEGAL ASPECTS AND SOCIO-ECONOMIC IMPLICATIONS REGARDING DRUG COUNTERFEITING CIOBANU CONSTANTIN, CORCIOVĂ ANDREIA Faculty of.

Slides:



Advertisements
Similar presentations
الرابطة الدولية لمكافحة المواد الطبيّة المزورة a WHO initiative to combat counterfeit medical products Dr V. Reggi - World Health Organization.
Advertisements

Copyright of the Health Sciences Authority 2007 ASEAN-China Conference on Combating Counterfeit Medical Products Jakarta, November 2007 Singapore.
IMPACT Principles and Elements for National Legislation Presented by: Chair, Working Group on Regulatory Implementation, on behalf of Chair, Working Group.
International Medical Products Anti-CounterfeitingTaskforce INSPECTOR OF DRUGS NATIONAL DRUG AUTHORITY- UGANDA.
Anti- Piracy Unit (APU) REPUBLIC OF MAURITIUS 1. MAURITIUS 2.
International Medical Products Anti-CounterfeitingTaskforce.
IMPACT REGIONAL CONFERENCE ON COMBATING COUNTERFEIT MEDICAL PRODUCT: 9-10 NOVEMBER 2009: KEMPTON PARK,SOUTH AFRICA: BY DETECTIVE INSPECTOR NAMIBIA.
First ASEAN-China Conference on Combating Counterfeit Medical Products Jakarta November 2007 CHOO CHEOK HANG DEPARTMENT OF PHARMACEUTICAL SERVICES.
Data Protection & Human Rights. Data Protection: a Human Right Part of Right to Personal Privacy Personal Privacy : necessary in a Democratic Society.
DG Enterprise and Industry Approach on Combating Counterfeit Medicines Council of Europe Conference “Europe against Counterfeit Medicines” Session: Key.
Tom Kubic Executive Director Pharmaceutical Security Institute World Bank Washington 10 March 2005 The Spreading Plague of Counterfeiting.
Panel themes of the International Conference “Europe against Counterfeit Medicines” G.N. Gildeeva, Deputy head of the Department of Registration of Medicines.
1 |1 | Counterfeit Medical Products: Anti-Counterfeit Medicines programme update Dr Lembit Rägo Coordinator Quality Assurance and Safety: Medicines Essential.
No /72, Level 2, Sri Balaji Mansion, Dr. Rajkumar Road, Rajajinagar 4th Block, Bangalore , India. Counterfeit Drug Detection | Fake Product.
- 0 - Medicines manufactured under these conditions What do you want your Patients to receive??
Strengthening the Protection of Intellectual and Industrial Property Rights Deputy Manager Jan Hylleberg The Danish Association of the Pharmaceutical Industry.
MeTa, Solwezi 27 August,2013.  A branded- name drug product is originally discovered and developed by a pharmaceutical company.  Branded-name drugs.
Introduction to Pharmacy Course Teacher: Asim Kumar Bepari.
The specific of training specialists in the field of Public Health in the Republic of Moldova.
University of Agricultural Sciences and Veterinary Medicine Cluj-Napoca, Romania Since 1869 Anti-microbial resistance – Urgent need to act in human and.
European Commission Enterprise and Industry Market surveillance and automotive type-approval legislation - 28/06/2012 | ‹#› WP.29 Enforcement Working Group.
Operational Material. 2 Presentation Outline Private Health Introduction Pharmaceutical Products Other Medical Products and Therapeutic Appliances Out-Patient.
Integration of Regulatory Impact Assessment into the decision making process in the Czech Republic Aleš Pecka Department of Regulatory Reform and Public.
Sabena Ahmad Iveta Smincakova Dawn Bradbury. Political:  Lighter Regulatory Controls (1960s)  Tighter Regulatory Controls on Clinical trials (1970s)
Pharma & Healthcare Logistics Development Roadmap for Luxembourg T h e r e i s s o m e t h i n g g o i n g o n i n L u x e m b o u r g ! T A S T r u s.
3rd Baltic Conference on Medicines Economic Evaluation, Reimbursement and Rational Use of Pharmaceuticals Pricing and Reimbursement of Pharmaceuticals.
> In April of 2007, Main Pharmaceutical Inspector created special position for combating counterfeit and illegal medicines > In May,
Ministerstwo Gospodarki Counterfeiting and other problems in plant protection products marketing (presentation of ) Zbigniew Barszcz Department.
South-East European Cooperation Process ROMANIA South-East European Cooperation Process (SEECP)
Agreement on Anti-Dumping Measures Anti - Dumping Importers would like to import goods if available at a price lower than that of the good in the importing.
The competition between innovative and generic pharmaceutical companies intensified in the last decades. The models created by innovative pharmaceutical.
THE UK EXPERIENCE RELATED TO CASE C- 185/10, COMMISSION v REPUBLIC OF POLAND DOES A “SPECIAL NEED” ARISE FOR AN UNLICENSED MEDICINE IF THE LICENSED EQUIVALENT.
Patient Safety: A Priority for the European Commission Mr Lee McGill Health and Consumers Directorate-General European Commission Royal College of Physicians.
Saving Lives, Saving Money Lilia Bounab – Healthcare Sales Manager EMEA Ar ł amów hotel, 14-16th June 2015.
 The pharmaceutical industry develops, produces, and markets drugs or pharmaceuticals licensed for use as medications.  Pharmaceutical companies are.
Principles of quality control of registered medicines, non- registered medicines and counterfeits of medical products Jean-Marc Spieser, Head of Department.
Ministry of Waters and Environmental Protection, ROMANIA 1 BERCEN 1 st Exchange program – November 2002 Croatia PROBLEMS AND SOLUTIONS IN COOPERATION.
1 Department of Medicines Policy and Standards, Health Technology and Pharmaceuticals WHO’s Role in Assuring the Quality Safety and Efficacy of Medicines:
S tefano S oro European Commission Health and Consumer Protection DG OBLIGATION OF PRODUCERS AND DISTRIBUTORS TO NOTIFY DANGEROUS PRODUCTS.
Bad intentions - good policies: Who wins? Case exercise and role play on drug counterfeiting in an LDC context World Bank Case Exercise – all names and.
ENVIRONMENTAL CHALANGE in connection with the BASEL CONVENTION IMPLEMENTATION MINISTRY OF ENVIRONMENT AND WATER MANAGEMENT OF ROMANIA General Directorate.
Cje Wojciech Jasiński, Ph.D. Department of Criminal Procedure Faculty of Law, Administration and Economics University of Wrocław Lecture Harmonisation.
Quality & Safety of Generic Drugs in the World Market World Bank Conference “Good Intentions – Bad Drugs” March 10, 2005 Washington, D.C. Christine Simmon.
“Supporting the Industry through Communication” The pharmaceutical industry is committed to the research, development, quality manufacturing and logistics.
By: Drew Perry. Counterfeit pharmaceutical drugs are fraudulently produced or mislabeled medicines purchased by consumers who believe them to be legitimate.
Issues related to poor IP protection in EMs: Pharmaceutical Example Rob May Commercial Director, Janssen, EMEA Emerging Markets.
Product Recall Laws in China Xiangwen Liu Partner King & Wood PRC Lawyers.
CONSUMER PROTECTION Slovak Customs Administration UNECE „MARS“ Group meeting 24 – 26 September 2006, Bratislava Bc. Viliam Pružinec, Customs Directorate.
EPHA Presentation Healthcare and social services treated equally as estate agents or advertising companies excluded from the Directive or Healthcare and.
Unfair commercial practice and B2C contracts in tourism Students: Lesia Mykhailenko Polina Dugina UNIFI, LM
TAIEX Workshop on the Implementation of EU Pharmacovigilance Legislation - BELGRADE CLAUDIA PANAIT TAIEX Expert – European Commission Legal Adviser.
Top 9 benefits of generic pharmacy Published by :
1 CHALLENGES IN REGULATION OF TRADITIONAL AND ALTERNATIVE MEDICINES 24 th March, 2010 MOHSW Conference Room Registration of Herbal Drugs.
Prepared by: Imon Rahman Lecturer Department of Pharmacy BRAC University.
CLAUDIA PANAIT TAIEX Expert – European Commission Legal Adviser Ministry of Health, ROMANIA.
Serbia Chapter 28 – Consumer and Health Protection Medicinal Products FALSIFIED MEDICINAL PRODUCTS Mira Kontic senior advisor for legislation Ministry.
M O N T E N E G R O Negotiating Team for the Accession of Montenegro to the European Union Working Group for Chapter 28 – Consumer and Health Protection.
EU Certification Systems Dr. Friedrich Lüdeke, GLOBALG.A.P. Cairo, 12 June 2012.
INTRODUCTION A national drug policy is a document which covers all the areas and issues related to drugs. This document outlines all aspects of drugs.
The Law of the KR «On making amendments and changes to certain legislative acts of the KR» 4 th MeTA Forum in the Kyrgyz Republic Bishkek, December 8,
EU Health Priorities Jurate Svarcaite Secretary General PGEU.
ACCESS TO QUALITY MEDICINES IN THE REGION-COUNTERFEITING PROBLEMS
THE NEW GENERAL DATA PROTECTION REGULATION: A EUROPEAN OR A GLOBAL STANDARD? Bart van der Sloot Senior Researcher Tilburg Institute for Law, Technology,
The Union’s Customs Code: the new European legal basis and its effects on international trade Roma, 7th September Cinzia Bricca Director of the Legislation.
Fight Against Falsified medicines
Medical Devices.
European response to Human trafficking
FUNDAMENTAL SOCIAL RIGHTS IN EU
EU Food Safety Requirements: - Hygiene of Foodstuffs -
Outline Background: development of the Commission’s position
Presentation transcript:

INTRODUCTION AND OBJECTIVES LEGAL ASPECTS AND SOCIO-ECONOMIC IMPLICATIONS REGARDING DRUG COUNTERFEITING CIOBANU CONSTANTIN, CORCIOVĂ ANDREIA Faculty of Pharmacy, Drug Analysis, Pharmaceutical Legislation and Deontology Department, Iași, România MATERIAL AND METHODS RESULTS CONCLUSIONS REFERENCES Medicine counterfeiting has become a worldwide problem affecting both the developing and developed countries and has grown into a real menace to the health system, pharmaceutical industry and of course to the patient safety(1). In 1992, the World Health Organization has developed a definition according to which “a counterfeit medicine is one which is deliberately and fraudulently mislabeled with respect to identity and/or source. Counterfeiting can apply to both branded and generic products and counterfeit products may include products with the correct ingredients or with the wrong ingredients, without active ingredients, with insufficient active ingredients or with fake packaging.” (2). The European law was compared with the Romanian legal provisions. The presented data analysis is related to: the number of counterfeit medicines the origin countries of the counterfeit medicines the therapeutic categories which are most frequently falsified and their estimated value. Falsified medicines pose a major threat to human health, therefore, a better involvement of the authorities and a better public cooperation in combating this phenomenon is necessary. The purpose of this paper was to present the legislative aspects relating to counterfeiting of medicines and the impact that this illegal activity has on the social and economic level. The paper also exposes some statistics provided by the World Health Organization and other international organisms involved in regulating the provisions of medicine’s domain. In Romania, the authorities are closely monitoring the issue of counterfeit medicines. In accordance with Directive 2011/62/EU all necessary measures were taken in order to prevent the falsified medicines from entering the legal supply circuit. According to article no. 834 of Law no. 95/2006 regarding the healthcare reform, any activity related to drug counterfeiting or the placing on the market of a falsified drug is a crime punishable by law. Specialized websites were also created ( where any cases of counterfeit drugs may be reported by the specialists in the pharmaceutical field and also by the population (3). In some developing countries, the most used categories of medicines are probably the antibiotics and antimalarics, so the counterfeiters focus on their "production". In many developed countries of the European Union, the most falsified medicines are those so-called “lifestyle medicines” such as those used in the weight loss and erectile dysfunction treatments (1). 1.World Health Organization, Substandard and Counterfeit Medicines. Fact Sheet No. 275, November. 2.World Health Organization Counterfeit medical products: Report by the secretariat. 3.Official Journal of the European Communities Directive 2011/62/EU of the European Parliament and Council. L 174. India China Egypt UAE Switzer Hong -land Kong